ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

SA Transcripts159.17K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer March 31, 2026 4:30 PM EDT Company Participants Dominic Piscitelli - Chief Financial OfficerJacob Chacko - President, CEO & DirectorLori Friedman - Chief Scientific OfficerPratik Multani - Chief Medical OfficerKeith Lui - Senior VP of Commercial & Medical Affairs Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research DivisionPrakhar Agrawal - Cantor Fitzgerald & Co., Research DivisionBradley Canino - Guggenheim Securities, LLC, Research DivisionMaurice Raycroft - Jefferies LLC, Research DivisionKelsey Goodwin - Piper Sandler & Co., Research DivisionColleen Hanley - Robert W. Baird & Co. Incorporated, Research DivisionYigal Nochomovitz - Citigroup Inc. Exchange ResearchCory Kasimov - Evercore ISI Institutional Equities, Research DivisionMatthew Biegler - Oppenheimer & Co. Inc., Research DivisionDavid Nierengarten - Wedbush Securities Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the ORIC Pharma Update Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Dominic Piscitelli. Please go ahead, sir. Dominic PiscitelliChief Financial Officer Welcome to the ORIC Pharmaceuticals rinzimetostat dose optimization data update call. Earlier today, we issued a press release highlighting new clinical data and details for our first Phase III trial. We have prerecorded our prepared remarks, after which we will host a live Q&A session. A replay of the webcast, along with the accompanying slides will be available on the Investor Relations section of our website for 90 days. Before we begin, during this call, we will be making forward-looking statements, including forward-looking statements based on our current expectations and projections about future events. Our actual results may differ materially from those indicated by such forward-looking statements. For a description of risk factors, please